Now prescribing BPC-157, TB-500, Semax, MOTS-c and Epitalon

PepScribe

Legal status

Is MOTS-c legal? How to get it prescribed in 2026. | Reddit

Last updated November 3, 2026

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

MOTS-c is not an FDA-approved drug. Since October 30, 2026, a licensed US pharmacy can compound it for you on a prescription. An HHS policy now lets licensed 503A pharmacies compound single-ingredient MOTS-c acetate as an injection for a named patient, under ten conditions. The policy is enforcement discretion, which is different from FDA approval, and HHS can revise it.

At PepScribe, a physician (MD) reviews your history online and decides whether MOTS-c fits you. The online visit is free, and you pay only if MOTS-c is prescribed. Below: how MOTS-c got here, from FDA Category 2 to the July 2026 advisory vote and the HHS policy, plus where it stands abroad and the risks of research-chemical vials.

Regulatory notice: MOTS-c is not an FDA-approved drug. Since October 30, 2026, an HHS policy lets licensed 503A pharmacies compound single-ingredient MOTS-c acetate as an injection for a patient with a prescription, under ten conditions. The policy is enforcement discretion, which is different from FDA approval, and HHS can revise it.

At PepScribe, a physician (MD) reviews your history and decides whether MOTS-c fits you. Get MOTS-c prescribed online with a free visit. This page is educational and is not medical advice.

Current US FDA status

MOTs-c has no FDA-approved drug application. No pharmaceutical company has taken MOTs-c through the New Drug Application (NDA) process, and no MOTs-c product has been approved for any indication. As a peptide compound, MOTs-c also does not qualify under the Dietary Supplement Health and Education Act (DSHEA) of 1994, so it is not a permitted dietary supplement ingredient.

Historically, MOTs-c was placed on the FDA’s Category 2 list of bulk drug substances. FDA defines Category 2 as bulk drug substances that raise significant safety concerns.

On April 15, 2026, the FDA published an update that removed MOTs-c, alongside a cohort of related peptides, from Category 2 because the nominations were withdrawn; FDA now lists it as a withdrawn nomination. MOTs-c is not in Category 1.

MOTs-c is not on FDA’s 503A Bulks List. On July 23, 2026, the Pharmacy Compounding Advisory Committee (PCAC) recommended adding it. That vote is advisory. Since October 30, 2026, HHS’s policy lets a licensed 503A pharmacy compound single-ingredient MOTS-c acetate as an injection for a named patient with a prescription, when ten conditions are met. They include an FDA-registered ingredient source, a certificate of analysis for every lot, one active ingredient and adverse-event reporting to FDA.

Every PepScribe prescription is filled by a licensed 503A pharmacy in the USA. No hidden overseas supply chain. A physician (MD) reviews your goals, history and current medications, then decides whether MOTS-c fits you.

The endogenous-vs-exogenous distinction

One of the most common arguments for regulatory leniency around MOTs-c runs roughly as follows: the body produces MOTs-c on its own, so administering more of it should not require the same regulatory machinery as a synthetic novel drug. The argument is appealing and partially correct, but it does not do the legal or pharmacological work that proponents tend to assume.

A useful comparison is insulin. Insulin is endogenous in nearly everyone. That fact does not make exogenous insulin a casual product. Insulin is tightly regulated, requires prescription, and is among the drugs most frequently involved in serious adverse events when it is dosed incorrectly, because the difference between a physiologic concentration and a pharmacologic concentration is the difference between regulation and dysregulation.

The same general logic applies to MOTs-c, which engages AMPK and influences glucose handling. Endogenous regulation involves feedback loops, tightly bounded concentrations, and tissue-level regulation that exogenous bolus dosing does not reproduce. The fact that the body makes MOTs-c is a reasonable starting framing, but it does not itself establish that exogenous administration is safe outside of clinical trials, nor does it provide a regulatory shortcut around the standard drug-approval process.

The legal framework reflects this. The FDA’s drug-approval and compounding categories are not waived for substances that have an endogenous origin. Hormones, growth factors, and peptide signals that are made in the body still go through the same approval and compounding pathways as any other therapeutic.

The CohBar pharmaceutical history and what it tells us

CohBar Inc. is the most informative case study in any discussion of the MOTs-c regulatory bar. CohBar was a USC spinout founded specifically to translate mitochondrial-derived peptide biology into pharmaceutical candidates, with direct ties to the original research group that characterized MOTs-c in 2015.

The company explored MDP-derived analog programs and advanced candidates into early clinical evaluation in the late 2010s and early 2020s. Despite the credibility of the underlying biology, the company’s intellectual property position, and access to capital, CohBar did not bring a MOTs-c- derived therapeutic to market. The company eventually wound down operations without a commercial launch.

For a regulatory analysis, the takeaway is concrete. The standard path to making MOTs-c, or a MOTs-c analog, an FDA-approved metabolic therapy requires the same kind of formal Phase 1, Phase 2, and Phase 3 clinical trial program that any new drug requires. CohBar attempted parts of that path. The path was not completed. Until that kind of trial program is run and publicly reported, there is no shortcut by which compounded MOTs-c becomes a clinically validated metabolic medication. Compounding posture is a regulatory question. Clinical validity is a trial-data question, and they are not the same thing.

503A compounding implications

The compounding picture for MOTs-c hinges on a few specific provisions of the Federal Food, Drug, and Cosmetic Act and the FDA’s implementation of those provisions.

  • Section 503A governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions. PepScribe partners with 503A pharmacies exclusively, which means every dose dispensed through this platform is prescribed by a licensed clinician, prepared by a licensed compounding pharmacy, and traceable to a US-based 503A facility.
  • Section 503B covers outsourcing facilities that can compound without individual prescriptions but must comply with current Good Manufacturing Practices (cGMP). Every PepScribe prescription is filled by a licensed 503A pharmacy.
  • Bulk drug substance lists govern what compounders can use as starting material. MOTs-c was in Category 2 until April 2026, when it was removed because the nomination was withdrawn. FDA defines Category 2 as bulk drug substances that raise significant safety concerns. MOTS-c is not in Category 1 or on the 503A Bulks List; HHS’s October 2026 policy covers it separately.

In practice, a physician can now prescribe MOTS-c after reviewing your history, and can weigh it against GLP-1 medicines and other options in the same visit.

Gray-market risks (with a metabolic-peptide twist)

Many of the gray-market risks that apply to research peptides in general, purity, sterility, identity, dosing accuracy, and adulteration, apply to MOTs-c just as they do to BPC-157 or TB-500. There is also a category of risk that is specific to a peptide that engages AMPK and influences glucose handling, and it is worth flagging directly.

Quality and identity risks shared with other gray-market peptides

  • Purity. Without pharmaceutical-grade synthesis and quality control, gray-market MOTs-c may contain incorrect peptide sequences, truncated chains, or entirely different peptides that happen to be cheaper or easier to produce.
  • Sterility. Injectable preparations carry endotoxin, bacterial, and fungal contamination risks that are particularly serious because the route of administration bypasses the body’s mucosal defenses entirely.
  • Concentration accuracy. A vial labeled as containing X milligrams of MOTs-c may contain substantially more or less, with no quality-assurance testing to verify.
  • Solvent and reagent residues. Uncontrolled synthesis can leave behind organic solvents, heavy metals, or reagent byproducts that appear nowhere on the label.
  • No pharmacovigilance. If something goes wrong, there is no adverse-event reporting infrastructure, and the patient and clinician have no clean record of what was in the vial.

Risks specific to a metabolically active peptide

MOTs-c engages a pathway (AMPK) that is centrally involved in glucose handling and that is the same pathway targeted by metformin. That mechanism has implications for how MOTs-c could interact with diabetes medications.

  • Insulin and sulfonylureas. A peptide that increases insulin sensitivity and increases skeletal-muscle glucose uptake can, in principle, lower blood glucose more than expected in a patient already on insulin or insulin-secretagogue therapy. The practical consequence of unrecognized interaction is hypoglycemia.
  • Metformin. Metformin is itself an AMPK-related agent. Adding a peptide that engages the same pathway in a patient already on metformin is a clinical-judgment question, not a self-administration question.
  • GLP-1 receptor agonists. Patients on semaglutide, tirzepatide, or related GLP-1-class therapies already have substantial pharmacologic engagement of glucose-handling pathways. Stacking an additional metabolically active peptide on top, without clinician oversight, is precisely the kind of thing that can produce unexpected outcomes.
  • Thyroid and other endocrine contexts. Patients with thyroid disease, adrenal disease, or established metabolic syndromes have endocrine systems that interact with the same energy-regulating pathways MOTs-c engages.

The summary is that MOTs-c is not a low-stakes peptide to self-administer without medical oversight, even leaving aside its regulatory status. The possibility that the substance interacts unpredictably with diabetes medications is a specifically clinical concern, not a theoretical one.

International picture: UK, Canada, Australia, EU

The MOTs-c regulatory picture outside the United States is, broadly, stricter than the US picture. None of the major regulatory jurisdictions have approved MOTs-c as a therapeutic.

United Kingdom

MOTs-c is not licensed as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It cannot be legally marketed as a medicine or sold for therapeutic use. The UK does not have a direct analogue of the US 503A compounding pathway, and any therapeutic access would require either an MHRA-approved product or a clearly defined special-use exemption, neither of which exists for MOTs-c. Products labeled as research chemicals exist online, but those products are not regulated for human use.

Canada

Health Canada has not approved MOTs-c as either a drug or a natural health product. It is not in the Drug Product Database or the Licensed Natural Health Products Database. Provincial pharmacy regulators govern compounding in Canada, and the framework for compounding peptides without an approved product is more restrictive than the US system. Importing MOTs-c for personal use from international sources may violate the Food and Drugs Act, particularly when the product is represented as therapeutic.

Australia

Australia’s Therapeutic Goods Administration (TGA) is among the strictest regulators for peptides globally. MOTs-c is not on the Australian Register of Therapeutic Goods (ARTG). The TGA has actively targeted the importation and sale of unapproved peptides, and Australian Border Force has seized peptide shipments at the border. Compounding pharmacies in Australia generally cannot prepare substances that are not TGA-approved without a specific exemption.

European Union

MOTs-c is not approved by the European Medicines Agency (EMA) and is not authorized for therapeutic use in any EU member state. EU pharmaceutical regulation generally requires either a centralized EMA authorization or a national-level authorization for a marketed product, neither of which exists for MOTs-c. Member states have varying approaches to compounding, but the absence of an approved product places MOTs-c outside the standard therapeutic-access framework EU-wide.

International takeaway

No major regulatory authority has approved MOTs-c for therapeutic use. In the US, it is not FDA-approved and not on FDA’s 503A Bulks List.

WADA and sport status

The World Anti-Doping Agency (WADA) maintains a Prohibited List of substances banned in sport. The list is reviewed and updated annually, and it includes broad categories such as peptide hormones, growth factors, related substances, and metabolic modulators, in addition to substances named explicitly.

MOTs-c has attracted WADA-adjacent interest precisely because of the exercise-mimetic framing in the scientific literature: a peptide that engages AMPK, increases skeletal-muscle glucose uptake, and shifts substrate use toward fatty acid oxidation overlaps with classes of agents that are already restricted in competitive sport. Based on public information at the time of writing, MOTs-c does not appear by name on the most recent Prohibited List, but the WADA framework includes a catch-all provision (S0) that prohibits substances which are not approved by any governmental regulatory health authority for human therapeutic use, when used by an athlete in competition.

That catch-all is directly relevant to MOTs-c. Because MOTs-c is not approved for human therapeutic use anywhere, an athlete subject to WADA jurisdiction who used MOTs-c could face consequences under S0 even in the absence of explicit named-substance listing. Competitive athletes should consult the current WADA Prohibited List directly and their sport’s anti-doping authority before considering any peptide, and they should treat MOTs-c as high-risk in this context.

Detection methodology is also evolving. Anti-doping laboratories have developed mass-spectrometry-based methods for synthetic peptides, and the absence of a positive test today does not guarantee future undetectability.

Possession vs sale: a critical distinction

Three different legal questions tend to get collapsed in conversations about peptide legality, and they are worth separating.

  1. Is possession criminalized? In the United States, MOTs-c is not a controlled substance. Possessing MOTs-c for personal use is unlikely to expose a person to criminal controlled-substance penalties. This is a different question from whether it is legal to sell, prescribe, or self-administer.
  2. Is sale for human use lawful? Selling MOTs-c for human consumption, in a way that holds it out as a therapeutic product, is not consistent with current FDA regulations. Vendors who do this often hide behind “for research use only” labels, which do not provide the legal protection their language suggests when context indicates the product is intended for human use.
  3. Is prescription dispensing lawful? Since October 30, 2026, yes, under HHS’s policy: a licensed 503A pharmacy may compound single-ingredient MOTS-c acetate as an injection for a patient with a prescription, under ten conditions.

None of these answers translate into “MOTs-c is legal to use, freely available, and clinically validated.” The summary: not criminalized, not FDA-approved, not on the 503A Bulks List, and unsupported by the kind of human trial data that would make it a validated metabolic therapy.

What reclassification would require

Patients and clinicians sometimes ask what it would take for MOTs-c to move from its current status into an approved therapeutic position. The answer is the standard drug-development path. There is no regulatory side door for an interesting endogenous peptide.

  • Phase 1 trials. Small, carefully monitored studies in healthy volunteers establish basic safety, tolerability, dosing range, and preliminary pharmacokinetics. CohBar attempted aspects of this kind of work for MDP-derived candidates without carrying a MOTs-c product to market.
  • Phase 2 trials. Larger studies in patients with the target condition (for example, type 2 diabetes, obesity, or a metabolic-syndrome population) establish preliminary efficacy and refine the dosing regimen.
  • Phase 3 trials. Large randomized controlled trials with clinical endpoints (such as A1c reduction, weight change, cardiovascular outcomes) generate the pivotal evidence required for approval.
  • FDA new drug application. A formal NDA with the trial data, manufacturing standards, labeling, and risk-management plan goes to the FDA for review.
  • Post-approval pharmacovigilance. An approved product carries ongoing safety monitoring obligations and potential post-marketing studies.

A separate step is FDA placing MOTs-c on the 503A Bulks List after PCAC review. PCAC recommended that on July 23, 2026; the vote is advisory. Neither step has been completed. HHS’s October 2026 policy is a separate route that lets a licensed 503A pharmacy compound MOTS-c on a prescription today.

MOTS-c or a GLP-1 medicine?

If weight loss is the main goal, semaglutide and tirzepatide have the larger human trial base: their reference brands are FDA-approved after large randomized trials. MOTS-c’s human evidence is early and mostly observational. A physician can weigh them in the same visit, and some patients ask about both.

See the MOTS-c plan, or compare semaglutide and tirzepatide.

Practical takeaways

  • MOTs-c is not FDA-approved and not on the 503A Bulks List. It was removed from Category 2 in April 2026 because the nomination was withdrawn, it is not in Category 1, and PCAC recommended adding it to the Bulks List on July 23, 2026 (advisory). Since October 30, 2026, HHS’s policy lets a licensed 503A pharmacy compound it on a prescription.
  • Every PepScribe prescription is filled by a licensed 503A pharmacy, and a physician (MD) decides whether MOTS-c fits you.
  • Endogenous origin is not a shortcut. The body making MOTs-c does not exempt exogenous administration from the standard regulatory and clinical-validation path.
  • CohBar attempted the full drug-approval path and did not bring a MOTs-c product to market. That is the most informative case study in any analysis of the regulatory bar.
  • Gray-market MOTs-c carries serious risks, including the metabolic-peptide-specific risk of unrecognized interaction with diabetes medications.
  • Internationally, no major regulator has approved MOTs-c. In the US, it is not FDA-approved and not on the 503A Bulks List.
  • For weight-loss goals, semaglutide and tirzepatide have the larger human trial base. A physician can weigh them against MOTS-c in the same visit.

Legal status

MOTs-c: questions, answered

If something is not here, reach out. We'd rather answer it than have you guess.

Is MOTs-c legal in the United States?

MOTs-c is not a controlled substance, so possessing it for personal use is unlikely to carry criminal controlled-substance penalties. However, it is not an FDA-approved drug and is not a permitted dietary supplement, and it is not on FDA's 503A Bulks List. Since October 30, 2026, an HHS policy lets licensed 503A pharmacies compound single-ingredient MOTS-c acetate as an injection for a patient with a prescription, under ten conditions. The policy is enforcement discretion, which is different from FDA approval, and HHS can revise it.

Is MOTs-c FDA-approved?

No. No pharmaceutical company has taken MOTs-c through the New Drug Application process, and no MOTs-c product has been approved for any indication. As a peptide compound it also does not qualify under the Dietary Supplement Health and Education Act, so it is not a permitted dietary supplement ingredient either.

Can a 503A pharmacy compound MOTs-c after the April 2026 update?

Yes, since October 30, 2026. HHS's policy covers single-ingredient MOTS-c acetate as an injection for a patient with a prescription. The pharmacy must meet ten conditions, including an FDA-registered ingredient source, a certificate of analysis for every lot and adverse-event reporting. MOTS-c is still not an FDA-approved drug.

Is MOTs-c legal outside the United States?

No major regulatory authority has approved MOTs-c for therapeutic use. It is not licensed by the UK MHRA, not approved by Health Canada, not on Australia's Register of Therapeutic Goods, and not authorized by the EMA or in any EU member state. In the US, it is not FDA-approved and not on FDA's 503A Bulks List.

What would it take for MOTs-c to become an approved metabolic therapy?

The standard drug-development path: Phase 1, Phase 2, and Phase 3 clinical trials followed by an FDA New Drug Application and post-approval pharmacovigilance. A separate step is FDA placing MOTs-c on the 503A Bulks List: PCAC recommended that on July 23, 2026; the vote is advisory. Neither step has been completed. HHS's October 2026 policy is a separate route: it lets a licensed 503A pharmacy compound MOTS-c on a prescription today.

How do I get MOTS-c prescribed online?

Start a free online visit at PepScribe. You answer a short medical intake, and a physician (MD) reviews your history, most within 24 hours, and decides whether MOTS-c fits you. If it is prescribed, a licensed 503A pharmacy in the USA fills your prescription for single-ingredient MOTS-c acetate, with your name on the label. You pay only if it is prescribed.

References

  1. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration (fda.gov).
  2. The Prohibited List. World Anti-Doping Agency (wada-ama.org) (2025).
  3. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration (fda.gov).
  4. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism — Lee C, et al., Cohen P (via PubMed) (2015).

Get MOTS-c by prescription.

A physician (MD) reviews your intake, most within 24 hours. The online visit is free, and you pay only if MOTS-c is prescribed.

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.